Streetbeat News

Analyst Ratings

GOL

Goldman Sachs analyst Bruno Amorim maintains a Neutral rating on Gol Linhas Aereas (NYSE:GOL) and lowers the price target from $3.1 to $2.65.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:57 pm

ENPH

Goldman Sachs analyst Brian Lee has maintained a 'Buy' rating on Enphase Energy (NASDAQ:ENPH) but lowered the price target from $180 to $158.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:56 pm

EA

Wedbush analyst Nick McKay has reiterated an 'Outperform' rating on Electronic Arts (NASDAQ:EA) and maintained a price target of $155.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:55 pm

JEPQ

MSFT

VFC

XHB

On CNBC's 'Halftime Report Final Trades', Bryn Talkington recommended JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Kevin Simpson highlighted Microsoft's (MSFT) strong Q1 results, and Jenny Harrington picked V.F. Corporation (VFC) ahead of its earnings report. Stephen Weiss is short on SPDR S&P Homebuilders ETF (XHB).

Portfolio Pulse from Lisa Levin

October 30, 2023 | 12:54 pm

COUR

Goldman Sachs analyst Eric Sheridan has maintained a Neutral rating on Coursera (NYSE:COUR) and raised the price target from $15 to $18.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:53 pm

TTWO

Wedbush analyst Nick McKay has reiterated an Outperform rating on Take-Two Interactive (NASDAQ:TTWO) and maintained a $165 price target.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:53 pm

DBD

Wedbush analyst Matt Bryson has reiterated a Neutral rating on Diebold Nixdorf (NYSE:DBD) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:51 pm

DAWN

DCPH

VYNE

Deciphera Pharma (DCPH) shares are up after its study of patients with TGCT met primary and secondary endpoints. Day One Biopharmaceuticals (DAWN) shares rose after the FDA accepted its NDA for tovorafenib in relapsed or progressive pediatric low-grade glioma, granted priority review and assigned a PDUFA date of April 30, 2024. VYNE Therapeutics (VYNE) shares increased after announcing a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo.

Portfolio Pulse from ryanfaloona@benzinga.com

October 30, 2023 | 12:50 pm

CHTR

Goldman Sachs analyst Brett Feldman has maintained a 'Buy' rating on Charter Communications (NASDAQ:CHTR) but lowered the price target from $510 to $450.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:49 pm

SMCI

Wedbush analyst Matt Bryson has reiterated a Neutral rating on Super Micro Computer (NASDAQ:SMCI) and maintained a $250 price target.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:48 pm